These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37081846)

  • 1. High intact fibroblast growth factor 23 levels associated with low hemoglobin levels in patients on chronic hemodialysis.
    Fang YW; Wang JT; Lin TY; Lee CJ; Jang TN; Tsai MH; Liou HH
    Front Med (Lausanne); 2023; 10():1098871. PubMed ID: 37081846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-Analysis of the Association between Fibroblast Growth Factor 23 and Mortality and Cardiovascular Events in Hemodialysis Patients.
    Gao S; Xu J; Zhang S; Jin J
    Blood Purif; 2019; 47 Suppl 1(Suppl 1):24-30. PubMed ID: 30699419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphate control in reducing FGF23 levels in hemodialysis patients.
    Rodelo-Haad C; Rodríguez-Ortiz ME; Martin-Malo A; Pendon-Ruiz de Mier MV; Agüera ML; Muñoz-Castañeda JR; Soriano S; Caravaca F; Alvarez-Lara MA; Felsenfeld A; Aljama P; Rodriguez M
    PLoS One; 2018; 13(8):e0201537. PubMed ID: 30086150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Iron and Erythropoietin in the Association of Fibroblast Growth Factor 23 with Anemia in Chronic Kidney Disease in Humans.
    Bielesz B; Reiter T; Hammerle FP; Winnicki W; Bojic M; Gleiss A; Kieweg H; Ratzinger F; Sunder-Plassmann G; Marculescu R
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32823844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-terminal and intact FGF23 in kidney transplant recipients and their associations with overall graft survival.
    Chu C; Elitok S; Zeng S; Xiong Y; Hocher CF; Hasan AA; Krämer BK; Hocher B
    BMC Nephrol; 2021 Apr; 22(1):125. PubMed ID: 33832449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Clearance of Fibroblast Growth Factor-23 (FGF23) and its Fragments in Humans.
    Sharma S; Katz R; Ginsberg C; Bullen A; Vallon V; Thomson S; Moe OW; Hoofnagle AN; de Leeuw PW; Kroon AA; Houben AJHM; Ix JH
    J Bone Miner Res; 2022 Jun; 37(6):1170-1178. PubMed ID: 35373859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Intact Fibroblast Growth Factor 23 Levels Are Negatively Associated with Bone Mineral Density in Chronic Hemodialysis Patients.
    Lee WT; Fang YW; Chen M; Liou HH; Lee CJ; Tsai MH
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients.
    Hanudel MR; Wesseling-Perry K; Gales B; Ramos G; Campbell V; Ethridge K; Scotti M; Elashoff DA; Alejos J; Reemtsen B; Salusky IB
    Pediatr Nephrol; 2016 Apr; 31(4):661-9. PubMed ID: 26525200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-terminal fragment of fibroblast growth factor 23 improves heart function in murine models of high intact fibroblast growth factor 23.
    Hu MC; Reneau JA; Shi M; Takahashi M; Chen G; Mohammadi M; Moe OW
    Am J Physiol Renal Physiol; 2024 Apr; 326(4):F584-F599. PubMed ID: 38299214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative changes of FGF23 in patients undergoing surgery for primary hyperparathyroidism.
    Fořtová M; Hanousková L; Valkus M; Čepová J; Průša R; Kotaška K
    Endocr Connect; 2022 Jan; 11(1):. PubMed ID: 34860179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Growth Factor 23 and Incident Cardiovascular Disease and Mortality in Middle-Aged Adults.
    Paul S; Wong M; Akhabue E; Mehta RC; Kramer H; Isakova T; Carnethon MR; Wolf M; Gutiérrez OM
    J Am Heart Assoc; 2021 Aug; 10(16):e020196. PubMed ID: 34387090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological variability of plasma intact and C-terminal FGF23 measurements.
    Smith ER; Cai MM; McMahon LP; Holt SG
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3357-65. PubMed ID: 22689697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay of erythropoietin, fibroblast growth factor 23, and erythroferrone in patients with hereditary hemolytic anemia.
    van Vuren AJ; Eisenga MF; van Straaten S; Glenthøj A; Gaillard CAJM; Bakker SJL; de Borst MH; van Wijk R; van Beers EJ
    Blood Adv; 2020 Apr; 4(8):1678-1682. PubMed ID: 32324886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?
    Bożentowicz-Wikarek M; Kocełak P; Owczarek A; Olszanecka-Glinianowicz M; Mossakowska M; Skalska A; Więcek A; Chudek J
    Clin Biochem; 2015 Apr; 48(6):431-6. PubMed ID: 25583093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
    Iwasaki T; Fujimori A; Nakanishi T; Okada S; Hanawa N; Hasuike Y; Kuragano T
    BMC Nephrol; 2021 Apr; 22(1):124. PubMed ID: 33832448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly.
    Chudek J; Kocełak P; Owczarek A; Bożentowicz-Wikarek M; Mossakowska M; Olszanecka-Glinianowicz M; Wiecek A
    Nephrol Dial Transplant; 2014 Sep; 29(9):1757-63. PubMed ID: 24729016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intact FGF23 predicts serum phosphate improvement after combined nicotinamide and phosphate binder treatment in hemodialysis patients.
    Egli-Spichtig D; Hamid AK; Arroyo EMP; Ketteler M; Wiecek A; Rosenkranz AR; Pasch A; Lorenz H; Hellmann B; Karus M; Ammer R; Rubio-Aliaga I; Wagner CA
    Clin Kidney J; 2023 Oct; 16(10):1622-1633. PubMed ID: 37779856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and Mortality in Renal Transplant Recipients.
    Eisenga MF; van Londen M; Leaf DE; Nolte IM; Navis G; Bakker SJL; de Borst MH; Gaillard CAJM
    J Am Soc Nephrol; 2017 Dec; 28(12):3639-3646. PubMed ID: 28774998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.